REASSESSMENT DYNAMICS OF ORPHAN DRUGS IN GERMANY'S BENEFIT ASSESSMENT PROCESS

被引：0
|
作者：
Chavez, D. [1 ]
Tolkmitt, F. [2 ]
Mills, M. [2 ]
Kanavos, P. [1 ]
机构：
[1] London Sch Econ & Polit Sci, London, England
[2] Hive Hlth Optimum Ltd, London, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PT7
引用
收藏
页码：S323 / S323
页数：1
相关论文
共 50 条
  • [21] HTA ASESSMENT COMPARISON OF ORPHAN DRUGS IN FRANCE AND GERMANY
    Remuzat, C.
    Mzoughi, O.
    Rodrigues, J.
    Korchagina, D.
    Toumi, M.
    VALUE IN HEALTH, 2014, 17 (03) : A236 - A237
  • [22] TECHNICAL RESERVES OF ORPHAN'S BENEFIT
    Hrubes, Jan
    APLIMAT 2005 - 4TH INTERNATIONAL CONFERENCE, PT I, 2005, : 423 - 430
  • [23] Early benefit assessment of new drugs in Germany - Results from 2011 to 2012
    Hoern, Helmut
    Nink, Katrin
    McGauran, Natalie
    Wieseler, Beate
    HEALTH POLICY, 2014, 116 (2-3) : 147 - 153
  • [24] THE GOOD THE BAD AND THE NON -QUANTIFIABLE - A COMPARISON OF REBATES ON ORPHAN DRUGS VERSUS NON-ORPHAN DRUGS IN GERMANY
    Wijnands, T.
    Schuchardt, M.
    Nijhuis, T.
    VALUE IN HEALTH, 2016, 19 (07) : A582 - A582
  • [25] Benefit Assessment in Germany REPLY
    Sawicki, Peter T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (04):
  • [26] ORPHAN DRUGS: OVERVIEW AND REGULATORY REVIEW PROCESS
    Thaker, Z.
    Jethva, K.
    Bhatt, D.
    Zaveri, M.
    Deshpande, S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2019, 10 (02): : 505 - 518
  • [27] Post-authorisation assessment of orphan drugs
    Hollak, Carla E. M.
    Biegstraaten, Marieke
    Levi, Marcel
    Hagendijk, Rob
    LANCET, 2015, 386 (10007): : 1940 - 1941
  • [28] AMNOG - SUMMARY OF OUTCOMES OF EARLY BENEFIT ASSESSMENT AND REIMBURSEMENT NEGOTIATION FOR NEW DRUGS IN GERMANY
    Claus, V
    Freyer, D.
    Kotowa, W.
    Mathes, J.
    VALUE IN HEALTH, 2012, 15 (07) : A316 - A316
  • [29] REPURPOSED DRUGS LAUNCHED UNDER THE AMNOG IN GERMANY: EFFECTS ON BENEFIT ASSESSMENT AND PRICE DEVELOPMENT
    Sake, S. M.
    Martyniszyn-Eiben, A.
    Zavatta, E.
    Gluesen, M.
    Berger, I
    Schoenermark, M.
    VALUE IN HEALTH, 2022, 25 (12) : S261 - S261
  • [30] COMPREHENSIVE REVIEW OF ORPHAN DRUGS POST-AMNOG IN GERMANY
    Leibfried, M. J.
    Jun, K.
    Neuner, C.
    Arsiwalla, M. Y.
    Richardson, S. K.
    VALUE IN HEALTH, 2015, 18 (07) : A681 - A681
12345